Prostate Cancer Clinical Trial

Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)

Summary

This retrospective observational multi centered study has been established to collect the clinical experience relating to the administration of Fluciclovine 18F employed in both investigator initiated studies and named patient/compassionate use programmes in up to 5 sites.

View Full Description

Full Description

This study will collect clinical data from consenting patients (unless a HIPAA waiver or equivalent was granted) who received the PET radiotracer Fluciclovine 18F (FACBC) (a synthetic amino acid analog) for imaging of patients with various cancers at participating sites in the US and Europe.

Data collection will cover baseline medical history and medications in all patients.

The result of PET radiotracer and other imaging findings, and reports of histopathology from biopsied tissue (where available) and in a time window relevant to the use of PET imaging in the diagnosis of primary/recurrent prostate cancer will be recorded.

In all subjects, with regards to safety monitoring, available data for physical examination, vital signs and laboratory test results will be collected from 28 days prior to and out to a 35 day window after Fluciclovine 18F (FACBC) administration.

The major goals of the investigation are to consolidate the safety profile of Fluciclovine 18F (FACBC), to evaluate its use in the detection of local and extraprostatic recurrence of prostate cancer and to evaluate its ability to detect malignancy in patients undergoing screening for primary prostate cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient managed by a site at which ethical committee approval for retrospective data collection under this protocol has been received
Patient has received at least one injection of fluciclovine (18F) for the detection of a malignant tumour at any location

Exclusion Criteria:

Subjects will be excluded from the analyses if any of the following criteria are met:
Patients participating in clinical trials or open access programmes at countries or sites not participating in this study.
Patients managed at sites without ethical committee approval for retrospective data collection under this protocol.

Study is for people with:

Prostate Cancer

Estimated Enrollment:

714

Study ID:

NCT02443571

Recruitment Status:

Completed

Sponsor:

Blue Earth Diagnostics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

Emory University Hospital
Atlanta Georgia, 30322, United States
University Hospital Sant'Orsola Malpighi
Bologna , 40138, Italy
Oslo University Hospital
Oslo , 0424, Norway
Aleris Kreftsenter
Oslo , N-026, Norway

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

714

Study ID:

NCT02443571

Recruitment Status:

Completed

Sponsor:


Blue Earth Diagnostics

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider